Evidence of PrEP use in first-time male voluntary blood donors from deidentified samples collected between 1 September 2018 and 31 May 2019 from 6 metropolitan locations
| Geographic location . | Samples . | PrEP drugs detected, n (%) . | Estimated days since last ARV dose, n (%) . | ||
|---|---|---|---|---|---|
| 1 d ago . | 2 d ago . | 3 d ago . | |||
| Boston, MA | 176 | 0 (0) | |||
| Los Angeles, CA | 344 | 2 (0.6) | 0 | 0 | 2 (100) |
| Miami, FL | 243 | 1 (0.4) | 0 | 1 (100) | 0 |
| New York, NY | 350 | 2 (0.6) | 0 | 0 | 2 (100) |
| San Francisco, CA | 211 | 2 (1.0) | 1 (50.0) | 1 (50.0) | 0 |
| Washington, DC | 170 | 2 (1.2) | 2 (100) | 0 | 0 |
| Total | 1494 | 9 (0.6)* | 3 (33.3) | 2 (22.2) | 4 (44.4) |
| Geographic location . | Samples . | PrEP drugs detected, n (%) . | Estimated days since last ARV dose, n (%) . | ||
|---|---|---|---|---|---|
| 1 d ago . | 2 d ago . | 3 d ago . | |||
| Boston, MA | 176 | 0 (0) | |||
| Los Angeles, CA | 344 | 2 (0.6) | 0 | 0 | 2 (100) |
| Miami, FL | 243 | 1 (0.4) | 0 | 1 (100) | 0 |
| New York, NY | 350 | 2 (0.6) | 0 | 0 | 2 (100) |
| San Francisco, CA | 211 | 2 (1.0) | 1 (50.0) | 1 (50.0) | 0 |
| Washington, DC | 170 | 2 (1.2) | 2 (100) | 0 | 0 |
| Total | 1494 | 9 (0.6)* | 3 (33.3) | 2 (22.2) | 4 (44.4) |
All samples with PrEP detected had with measurable levels of both TFV and FTC.
95% CI, 0.03% to 1.1%.